BioSpace News Archive

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent corporate developments.

Biohaven Pharmaceuticals announced that Nurtec® ODT will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program.

In terms of revenue, the global adhesion barriers market is projected to expand at a CAGR of ~ 7% during the forecast period, owing to numerous factors, regarding which, TMR offers thorough insights and forecasts in the adhesion barriers market report.

In accordance with the newsletter that was published the 5th of January 2021, Erik Penser Bank has now begun the implementation of a number of commissioned analyses, the first of which has been published and is available on ChemoTech’s website in English

Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in two upcoming investor conferences

PharmaEssentia USA Corporation announced the resubmission of its Biologics License Application to the U.S. Food and Drug Administration, seeking approval for ropeginterferon alfa-2b-njft for the treatment of polycythemia vera, a rare blood cancer.

Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations

Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global biotherapeutics leader driven by its promise to save and improve lives, are excited to announce that Dr. Minnie Sarwal of NephroSant was selected as the winner of the Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation.

MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market.